Abstract
The success of allogeneic stem cell transplantation (allo-SCT) in children is mainly affected by relapse or graft rejection. We have recently shown in a study of 55 patients with acute leukemias (ALL 21, AML 20 and MDS 14), that patients who demonstrate increase amounts of autologous marrow repopulation (increasing mixed chimerism) have a significantly enhanced risk of relapse (P < 0.0001). based on these findings, we asked whether post-transplant relapse can be prevented by withdrawal of immunosuppression and/or by donor lymphocyte infusion (dli). we describe the results of a pilot study where adoptive immunotherapy was used to treat 12 patients (five all, three aml, four mds) who showed increasing mixed chimerism (mc) post-transplant. a response to immunotherapy, defined as the re-establishment of complete chimerism (cc) and continuous complete remission (ccr), was achieved in four patients (two all, two aml) following withdrawal of csa and in a further six patients (three all, three mds) after additional dli. one all patient, who initially responded to dli, developed severe gvhd that required further immunosuppression. gvhd was controlled but this patient subsequently relapsed. another patient with all became a cc but developed an isolated relapse in the bone marrow 260 days later. one patient with mds developed severe gvhd after dli and died. two children (one aml and one mds) did not show any response to interventional treatment and died due to relapse. of the 12 patients treated, seven remain in ccr at a median follow-up of 747 days (range 351–1109 days). in summary, these results provide evidence that increasing mc can be used to guide adoptive immunotherapy strategies and that these treatment modalities can be used to prevent relapse in children with acute leukemias or mds after allo-sct.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bader, P., Klingebiel, T., Schaudt, A. et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 13, 2079–2086 (1999). https://doi.org/10.1038/sj.leu.2401581
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401581
Keywords
This article is cited by
-
Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15
Bone Marrow Transplantation (2022)
-
Retrospective, Landmark Analysis of Long-term Adult Morbidity Following Allogeneic HSCT for Inborn Errors of Immunity in Infancy and Childhood
Journal of Clinical Immunology (2022)
-
Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study
Blood Cancer Journal (2021)
-
Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients
Bone Marrow Transplantation (2015)
-
Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation
Bone Marrow Transplantation (2015)